Onyx Rebuffs Amgen, Seeks Other Bidders

Onyx Pharmaceuticals said it is now seeking potential buyers after rejecting an unsolicited acquisition proposal from Amgen that valued the cancer-drug maker at around $8.7 billion, based on shares outstanding.

Speak Your Mind

Subscribe to get this amazing EBOOK FREE

Real Estate 101 - Buying Your First Home!

By subscribing to this newsletter you agree to our Privacy Policy